Prostate Cancer Treatment ARX517 Granted FDA Fast Track Designation by admin_63069 | Aug 14, 2023 | News You Can Use The Food and Drug Administration is reportedly expediting the review of Ambrx’s treatment for patients with metastatic, castration-resistant prostate cancer that has displayed promising early trial results.
